AR094725A1 - Parvovirus 5a porcino, métodos de uso y vacuna - Google Patents
Parvovirus 5a porcino, métodos de uso y vacunaInfo
- Publication number
- AR094725A1 AR094725A1 ARP130104775A ARP130104775A AR094725A1 AR 094725 A1 AR094725 A1 AR 094725A1 AR P130104775 A ARP130104775 A AR P130104775A AR P130104775 A ARP130104775 A AR P130104775A AR 094725 A1 AR094725 A1 AR 094725A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- acid sequence
- nucleic acid
- polypeptide
- nucleotide sequences
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000125945 Protoparvovirus Species 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 8
- 150000007523 nucleic acids Chemical group 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 241000702619 Porcine parvovirus Species 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 244000144980 herd Species 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Secuencias de nucleótidos, secuencias de proteínas, composiciones inmunogénicas, vacunas y métodos que se refieren a la obtención y al uso de un parvovirus porcino 5A (PPV5A) que infecta, entre otros, a los cerdos domésticos. Las composiciones y los métodos detectan infecciones causadas por los virus, controlan los cambios genéticos de las secuencias virales en animales y manadas salvajes y domésticas, y permiten la obtención y el uso de vacunas para proteger los animales contra la infección causada por el virus. Reivindicación 1: Un polinucleótido aislado, caracterizado porque comprende un polinucleótido a) que tiene la secuencia de ácidos nucleicos de SEQ ID Nº 1; b) que tiene una secuencia de ácidos nucleicos que codifica un polipéptido de SEQ ID Nº 2, SEQ ID Nº 3 o SEQ ID Nº 4; c) que tiene una secuencia de ácidos nucleicos que es 80% idéntica a SEQ ID Nº 1, que codifica un polipéptido que tiene una actividad eficaz desde el punto de vista inmunológico o biológico, de un polipéptido de SEQ ID Nº 2, SEQ ID Nº 3 o SEQ ID Nº 4; d) que es un fragmento de una secuencia de ácidos nucleicos de SEQ ID Nº 1, que comprende al menos 30 secuencias de nucleótidos contiguos de SEQ ID Nº 1, o e) que es un fragmento de la secuencia de ácidos nucleicos de SEQ ID Nº 1, que comprende al menos 30 secuencias de nucleótidos contiguos de SEQ ID Nº 1, y que codifica una actividad eficaz desde el punto de vista inmunológico, de una secuencia de aminoácidos de SEQ ID Nº 2, SEQ ID Nº 3 o SEQ ID Nº 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738110P | 2012-12-17 | 2012-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094725A1 true AR094725A1 (es) | 2015-08-26 |
Family
ID=50931160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104775A AR094725A1 (es) | 2012-12-17 | 2013-12-16 | Parvovirus 5a porcino, métodos de uso y vacuna |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20140170180A1 (es) |
| EP (1) | EP2931741B1 (es) |
| AR (1) | AR094725A1 (es) |
| AU (1) | AU2014203571B2 (es) |
| CA (1) | CA2894708A1 (es) |
| CL (1) | CL2015001689A1 (es) |
| CO (1) | CO7461133A2 (es) |
| DK (1) | DK2931741T3 (es) |
| EA (1) | EA031278B1 (es) |
| ES (1) | ES2689515T3 (es) |
| MX (1) | MX2015007723A (es) |
| PH (1) | PH12015501378A1 (es) |
| SG (1) | SG11201504805PA (es) |
| TW (2) | TW201920662A (es) |
| UA (1) | UA117467C2 (es) |
| WO (1) | WO2014099669A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140170180A1 (en) | 2012-12-17 | 2014-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5a, methods of use and vaccine |
| US20140234354A1 (en) | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
| CA2944865C (en) * | 2014-04-17 | 2022-05-03 | Intervet International B.V. | Novel porcine parvovirus |
| WO2016210097A1 (en) * | 2015-06-23 | 2016-12-29 | The Trustees Of Columbia University In The City Of New York | Novel equine parvovirus and uses thereof |
| US10660952B2 (en) | 2016-11-03 | 2020-05-26 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
| UA127859C2 (uk) | 2016-11-03 | 2024-01-31 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Вакцина проти свинячого парвовірусу |
| KR102243368B1 (ko) * | 2019-04-17 | 2021-04-23 | 대한민국 | 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도 |
| CN111454969B (zh) * | 2019-09-02 | 2022-08-26 | 西北农林科技大学 | 带有双标签猪细小病毒全长感染性克隆制备方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| EP0117767A1 (en) | 1983-01-07 | 1984-09-05 | Mgi Pharma, Inc. | Production of parvovirus subunit vaccines |
| EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
| US4567043A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
| US4567042A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| EP0932694A2 (en) * | 1996-09-11 | 1999-08-04 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Aav4 vector and uses thereof |
| US20030049647A1 (en) * | 2001-02-22 | 2003-03-13 | Bassil Dahiyat | Use of nucleic acid libraries to create toxicological profiles |
| AU2010321784B2 (en) | 2009-11-23 | 2014-04-24 | Research Development Foundation | Recombinant filaggrin polypeptides for cell importation |
| US20140170180A1 (en) | 2012-12-17 | 2014-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5a, methods of use and vaccine |
| US20140234354A1 (en) | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
| CA2944865C (en) | 2014-04-17 | 2022-05-03 | Intervet International B.V. | Novel porcine parvovirus |
| EP3233890B1 (en) | 2014-12-19 | 2019-02-06 | Intervet International B.V. | Pestivirus |
| CN108135993B (zh) | 2015-08-31 | 2022-03-22 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 用于先天性震颤的瘟病毒疫苗 |
| UA127859C2 (uk) | 2016-11-03 | 2024-01-31 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Вакцина проти свинячого парвовірусу |
-
2013
- 2013-03-12 US US13/796,621 patent/US20140170180A1/en not_active Abandoned
- 2013-12-16 TW TW107130755A patent/TW201920662A/zh unknown
- 2013-12-16 AR ARP130104775A patent/AR094725A1/es unknown
- 2013-12-16 TW TW102146453A patent/TWI656213B/zh not_active IP Right Cessation
-
2014
- 2014-01-15 ES ES13814791.3T patent/ES2689515T3/es active Active
- 2014-01-15 SG SG11201504805PA patent/SG11201504805PA/en unknown
- 2014-01-15 DK DK13814791.3T patent/DK2931741T3/en active
- 2014-01-15 EA EA201500643A patent/EA031278B1/ru not_active IP Right Cessation
- 2014-01-15 UA UAA201506962A patent/UA117467C2/uk unknown
- 2014-01-15 MX MX2015007723A patent/MX2015007723A/es active IP Right Grant
- 2014-01-15 WO PCT/US2013/075059 patent/WO2014099669A1/en active Application Filing
- 2014-01-15 CA CA2894708A patent/CA2894708A1/en not_active Abandoned
- 2014-01-15 AU AU2014203571A patent/AU2014203571B2/en not_active Ceased
- 2014-01-15 EP EP13814791.3A patent/EP2931741B1/en not_active Revoked
-
2015
- 2015-05-15 US US14/713,700 patent/US9833507B2/en active Active
- 2015-06-16 CL CL2015001689A patent/CL2015001689A1/es unknown
- 2015-06-17 PH PH12015501378A patent/PH12015501378A1/en unknown
- 2015-07-17 CO CO15166795A patent/CO7461133A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2931741T3 (en) | 2018-10-22 |
| ES2689515T3 (es) | 2018-11-14 |
| CA2894708A1 (en) | 2014-06-26 |
| WO2014099669A1 (en) | 2014-06-26 |
| PH12015501378B1 (en) | 2015-09-02 |
| SG11201504805PA (en) | 2015-07-30 |
| MX2015007723A (es) | 2015-09-23 |
| PH12015501378A1 (en) | 2015-09-02 |
| CL2015001689A1 (es) | 2016-09-09 |
| EP2931741B1 (en) | 2018-07-25 |
| US9833507B2 (en) | 2017-12-05 |
| CO7461133A2 (es) | 2015-11-30 |
| EP2931741A1 (en) | 2015-10-21 |
| EA031278B1 (ru) | 2018-12-28 |
| US20150246113A1 (en) | 2015-09-03 |
| TW201920662A (zh) | 2019-06-01 |
| TWI656213B (zh) | 2019-04-11 |
| US20140170180A1 (en) | 2014-06-19 |
| UA117467C2 (uk) | 2018-08-10 |
| AU2014203571B2 (en) | 2017-09-28 |
| TW201437369A (zh) | 2014-10-01 |
| AU2014203571A1 (en) | 2015-06-11 |
| EA201500643A1 (ru) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| DK1881845T3 (da) | Nipah-virusvacciner | |
| DK1951296T4 (da) | Celleafledte viral vacciner med lave niveauer af restcelle-DNA | |
| NZ735684A (en) | Materials and methods for respiratory disease control in canines | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| AR124928A2 (es) | Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma | |
| BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| ME01140B (me) | Virus goveđe virusne dijareje s modifikovanim erns proteinom | |
| EA201990717A1 (ru) | Новая вакцина против гриппа свиней | |
| BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| AR085800A1 (es) | Vacuna de rinitis equina | |
| TW200801034A (en) | Novel sea lice vaccine | |
| MX2021015938A (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino. | |
| EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
| RU2013107777A (ru) | Поливалентная вакцина против гриппа на основе гибридного белка | |
| RU2020100038A (ru) | Материалы и методы, используемые для лечения респираторных заболеваний у собак | |
| PE20130341A1 (es) | Vacuna de adn contra el virus de la fiebre amarilla | |
| AR106463A1 (es) | Vacunas de ácido nucleico para el virus varicela-zóster (vzv) | |
| BR112019008624A2 (pt) | uso de um peptídeo secretagogo do hormônio do crescimento, composição de vacina, e, método para melhorar a resposta imune contra um antígeno de vacina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |